Zur Pressemappe der Preisverleihung 2009 - Deutsches Netzwerk ...
Zur Pressemappe der Preisverleihung 2009 - Deutsches Netzwerk ...
Zur Pressemappe der Preisverleihung 2009 - Deutsches Netzwerk ...
Sie wollen auch ein ePaper? Erhöhen Sie die Reichweite Ihrer Titel.
YUMPU macht aus Druck-PDFs automatisch weboptimierte ePaper, die Google liebt.
Lebenslauf<br />
Univ.-Prof. Dr. Uwe Siebert, MPH, MSc<br />
Preisträger des David-Sackett-Preises <strong>2009</strong><br />
Professor, Department Chair<br />
Institute for Public Health<br />
Medical Decision Making and Health Technology Assessment<br />
UMIT – University for Health Sciences, Medical Informatics and Technology<br />
E-Mail: public-health@umit.at<br />
Education<br />
MD (Univ. Munich), MPH (Univ. Munich), ScD (Univ. Harvard); Board Certificate in<br />
Epidemiology (GMDS),<br />
Board Certificate in Medical Biostatics (GMDS)<br />
Professional employment<br />
Department Chair at UMIT, Professor of Public Health (UMIT)<br />
Adjunct Professor of Health Policy and Management (Harvard School of Public<br />
Health)<br />
Director Cardiovascular Research Associate Professor of Radiology (Harvard<br />
Medical School)<br />
Further skills and competences<br />
Functions in national and international organizations and scientific networking<br />
Trustee, Society of Medical Decision Making (SMDM)<br />
Member of the Latin America Consortium Advisory Committee of the International<br />
Society of Pharmacoeconomics and Outcomes Research (ISPOR)<br />
Advisory Board Ludwig Boltzmann Institute for Health Technology Assessment,<br />
Vienna, Austria<br />
Co-Chair, Issues in Methodology Section of the Society of Medical Decision Making<br />
(SMDM) Policy Initiative<br />
Chair, Working Group Health Economics, German Society of Medical Informatics,<br />
Biostatistics and Epidemiology (GMDS)<br />
Chair, Working Group Medical Decision Making, GMDS<br />
Co-Editor, Medical Decision Making<br />
Research topic:<br />
HTA Methods and Translating HTA into Decision Making; Benefit-risk tradeoff of<br />
public health interventions; Pharmacogenomics and personalized medicine;<br />
Assessment of health-related programs; Planning, implementation and evaluation of<br />
epidemiologic studies, clinical trials, meta-analyses, risk-benefit assessments and<br />
economic evaluations<br />
39